Glyco-engineering of biotherapeutic proteins in plants

Cited 0 time in scopus
Metadata Downloads
Glyco-engineering of biotherapeutic proteins in plants
K Ko; M H Ahn; M Song; Y K Choo; Hyun Soon Kim; K Ko; Hyouk Joung
Bibliographic Citation
Molecules and Cells, vol. 25, no. 4, pp. 494-503
Publication Year
Many therapeutic glycoproteins have been successfully generated in plants. Plants have advantages regarding practical and economic concerns, and safety of protein production over other existing systems. However, plants are not ideal expression systems for the production of biopharmaceutical proteins, due to the fact that they are incapable of the authentic human N-glycosylation process. The majority of therapeutic proteins are glycoproteins which harbor N-glycans, which are often essential for their stability, folding, and biological activity. Thus, several glyco-engineering strategies have emerged for the tailor-making of N-glycosylation in plants, including glycoprotein subcellular targeting, the inhibition of plant specific glycosyltranferases, or the addition of human specific glycosyltransferases. This article focuses on plant N-glycosylation structure, glycosylation variation in plant cell, plant expression system of glycoproteins, and impact of glycosylation on immunological function. Furthermore, plant glyco-engineering techniques currently being developed to overcome the limitations of plant expression systems in the production of therapeutic glycoproteins will be discussed in this review.
glycoproteinglycosylationmolecular biopharmingmonoclonal antibodyrecombinant proteintransgenic plant
Korea Soc-Assoc-Inst
Appears in Collections:
Division of Research on National Challenges > Plant Systems Engineering Research > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.